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Abstract
Background: HMG-CoA reductase inhibitors, statins, are widely prescribed to lower cholesterol.
High doses of orally administered simvastatin has previously been shown to improve fracture
healing in a mouse femur fracture model. In this study, simvastatin was administered either
subcutaneously or directly to the fracture area, with the goal of stimulating fracture repair at
acceptable doses.
Methods: Femur fractures were produced in 70 mature male Balb-C mice and stabilized with
marrow-nailing. Three experiments were performed. Firstly, 20 mice received subcutaneous
injections of either simvastatin (20 mg) or vehicle. Secondly, 30 mice were divided into three
groups of 10 mice receiving continuous subcutaneous delivery of the vehicle substance, the vehicle
with 5 mg or with 10 mg of simvastatin per kg bodyweight per day. Finally, in 20 mice, a silicone
tube was led from an osmotic mini-pump to the fracture area. In this way, 10 mice received an
approximate local dose of simvastatin of 0.1 mg per kg per day for the duration of the experiment
and 10 mice received the vehicle compound. All treatments lasted until the end of the experiment.
Bilateral femurs were harvested 14 days post-operative. Biomechanical tests were performed by
way of three-point bending. Data was analysed with ANOVA, Scheffé's post-hoc test and Student's
unpaired t-test.
Results:  With daily simvastatin injections, no effects could be demonstrated for any of the
parameters examined. Continuous systemic delivery resulted in a 160% larger force at failure.
Continuous local delivery of simvastatin resulted in a 170% larger force at failure as well as a
twofold larger energy uptake.
Conclusion: This study found a dramatic positive effect on biomechanical parameters of fracture
healing by simvastatin treatment directly applied to the fracture area.
Background
In 1999, Mundy et al described a set of experiments, which
indicated that a group of common cholesterol lowering
drugs, the statins, have anabolic effects on bone[1]. Other
experiments supporting this finding have followed [2-11].
However, other studies have not shown any such effect,
most notably the study reported by Maritz et al, which in
essence repeated the study by Mundy et al and found dia-
metrically different results[12]. Also the experiments
reported by von Stechow et al found no positive effect on
undisturbed bone by simvastatin in mice[13]. Thus, there
still remains some controversy concerning the effect of
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statins on bone formation. In 2002, the authors reported
on a dramatic improvement of fracture repair in mice by
simvastatin mixed in the feed[14].
Although effective, the dose used in that study (about 100
times the recommended maximum clinical dose, as set
out in the official label text) seemed impractical if statins
were to have any use in bone formation in a clinical situ-
ation.
Most of the orally administered simvastatin in our previ-
ous study would have been sequestered in the liver, as
only a few per cent of orally administered simvastatin
reaches the general circulation in an unbound form and
are accessible to extra-hepatic cells (Official label text, [15-
18]). Consequently, in order to achieve a dose which
would be clinically useful, we would need to by-pass this
first pass clearance of the liver. We therefore conducted a
number of experiments on fracture repair in which we
administered the simvastatin as one daily subcutaneous
injection in doses ranging from 1 to 100 mg/kg body
weight. We were unable to find any significant effect of the
statins with this setup (data not shown).
With one daily injection, the concentration of simvastatin
would reach a peak relatively quickly, and then leave the
organism. The elimination half-life of simvastatin is about
2 hours in humans, and probably not longer in
mice[19,20].
Consequently, two questions arose. Firstly, is a continu-
ous plasma concentration necessary for an effect on frac-
ture repair? If so, subcutaneous injections would not
work, whereas a continuous subcutaneous release of sim-
vastatin would yield positive results similar to the ones
achieved when mixing it in the feed. Secondly, since the
effect of simvastatin on bone metabolism seems to be a
local effect on bone cells; would local delivery to the frac-
ture work?
In order to answer these questions, we performed three
experiments. Firstly, we conducted an expanded experi-
ment with subcutaneous injections. Secondly, subcutane-
ously implanted osmotic mini-pumps were used to
deliver a continuous systemic dose of simvastatin.
Thirdly, silicone tubes were led subcutaneously from
implanted osmotic mini-pumps to the fracture area, deliv-
ering a local continuous dose.
Methods
70 mature male Balb-C mice were used. The study had
been approved by the regional ethics board and institu-
tional guidelines for the care and treatment of laboratory
animals were adhered to. The mice were kept 1 per cage
with free access to mouse-chow and water.
Simvastatin powder (kindly supplied by MSD) was dis-
solved in PEG 400 (Sigma-Aldritch Chemie Gmbh, Stein-
heim, Germany) and passed through a sterile filter
(Millex™, pore-size 0.22 µm, Millipore Corporation)
before injection or filling the mini-pumps.
Surgical procedure
The mice were anesthetized with isoflourane gas. Each
mouse received a preoperative subcutaneous injection of
1.5 mg oxytretracycline and 0.003 mg of buprenorphine.
Implants and surgical equipment were sterilized in an
autoclave. Sterile gowns, gloves, surgical masks and thea-
tre caps were used. The mouse leg on the operated side
was shaved and the entire mouse was put into a sterile sur-
gical glove. Subsequently, a hole was cut out of the glove
and the leg pulled out through the hole using tweezers
and the leg washed with chloro-hexidine alcohol.
A lateral incision was made along the distal femur. The
patella was dislocated medially with the blunt side of the
scalpel, so that the femoral condyles were exposed. Using
an intercondylar approach, a hole was drilled through the
medullary canal of the femur using a cannula (diameter
0.4 mm). A wider cannula (0.6 mm) was then inserted
into the canal made. The sharp end of the cannula was
blunted in order not to penetrate through to the hip. The
cannula was cut off, so that the remaining bit was inside
the bone and no end extended beyond the bone. A spe-
cially made pair of scissors with semi-lunar cutting edges
were then slid along the bone to mid-diaphysis and the
femur cut to produce a fracture (Figures 1, 2 & 3). The
patella was then repositioned over the knee-joint and the
muscles and skin sutured separately.
Systemic treatment, subcutaneous injections
20 mice were used. The simvastatin powder was dissolved
in PEG-400 so as to ascertain a concentration of 1 mg/ml.
Starting on the day of surgery, subcutaneous injections of
approximately 20 mg per kg body weight per day were
administered in the scruff to 10 mice for 14 days. The
remaining 10 mice received vehicle injections.
Systemic treatment, osmotic mini-pumps
30 mice were used. On the day of surgery, the simvastatin
powder was dissolved in PEG-400 so as to ascertain the
proper concentrations. In the same session as when pro-
ducing the fractures, Alzet osmotic mini-pumps (B & K
Universal AB, Sollentuna, Sweden) for continuous release
of 0.25 microL per hour were subcutaneously implanted
in the scruff. Treatment was blinded to the operator and
randomised before surgery by drawing lots. Treatment
was divided into 3 groups of 10 mice, receiving the vehicle
substance (PEG-400), the vehicle with 5 mg (c = 20.8 mg/
ml) or with 10 mg (c = 41.6 mg/ml) of simvastatin per kg
bodyweight every 24 hours for 14 days.BMC Musculoskeletal Disorders 2007, 8:98 http://www.biomedcentral.com/1471-2474/8/98
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Local treatment, osmotic mini-pumps
20 mice were used. The simvastatin powder was dissolved
in PEG-400 so as to ascertain a concentration of 0.416
mg/ml. A silicone tube was subcutaneously led from the
implanted osmotic mini-pump to the fracture area and
fixed in place with a single 6.0 monofil suture in the adja-
cent muscle. Treatment was randomised before surgery by
drawing lots. The mini-pumps had a release profile which
meant that approximately 0.25 microL was released per
hour and 0.1 mg of simvastatin per kg bodyweight was
released to the area every 24 hours for 14 days. In this way,
10 mice received a local dose of simvastatin for the dura-
tion of the experiment and 10 mice received the vehicle
substance.
Evaluation
The mice were sacrificed at 14 days. Bilateral femurs were
harvested, the marrow-nail extracted and the maximal
sagittal and transverse diameters of the callus and the
mid-diaphysis of the unoperated femurs were measured
with a digital calliper. Biomechanical tests were per-
formed by way of three-point bending (beam length 6
mm) in a computerised machine (100 R, DDL Inc., Eden
Praire, Mn, USA) (Figures 3a & 3b). The bending force was
applied in the sagittal plane. Mechanical data evaluated
were force at failure (N), energy (Nmm) until 10% droop
from maximum force along the load- deformation curve
and Young's modulus of elasticity (MPa). All evaluations
were performed while blinded as to treatment.
For the subcutaneous injections, results were analysed
with Student's t-test. For the systemic mini-pump experi-
Photographs taken at evaluation to illustrate the three-point  bending Figure 2
Photographs taken at evaluation to illustrate the three-point 
bending.
A
B  Overview of experimental set-up Figure 1
Overview of experimental set-up. After insertion of the 
intramedullary cannula,, the specially made pair of scissors 
with semi-lunar cutting edges was slid along the bone to 
approximately mid-diaphysis and the femur cut.BMC Musculoskeletal Disorders 2007, 8:98 http://www.biomedcentral.com/1471-2474/8/98
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ment, statistical analysis was carried out with ANOVA, fol-
lowed by Scheffé's post-hoc analysis for comparisons
between groups. For the local treatment, results were ana-
lysed with Student's t-test.
Results
The mice recovered well after surgery and did not display
overt signs of discomfort. Weight-bearing on the operated
leg began within the first post-operative week.
In the subcutaneous injections experiment, 2 mice were
excluded because of faulty placement of the intramedul-
lary pins. In the systemic continuous release experiment,
4 mice were excluded. One due to failed surgery, one due
to death shortly after surgery and 2 due to technical errors
while harvesting the femurs. In the local treatment exper-
iment, one femur was excluded due to faulty intramedul-
lary pin placement. Exclusions were done while blinded.
Subcutaneous injections
No effects could be demonstrated for any of the parame-
ters examined (Table 1).
Continuous systemic delivery
Simvastatin (5 mg/kg/day) resulted in a 160 per larger
force at failure and an insignificant trend towards
increased modulus and energy (Table 2). Biomechanical
effects could not be found for the contra lateral, unbroken
femurs.
Local delivery
For the operated femurs, simvastatin treatment resulted in
a 170% larger force at failure as well as a 200% greater
energy uptake. Callus size was not significantly affected.
Modulus of elasticity displayed a trend towards higher
values as a result of the simvastatin, but this was not sig-
nificant (Table 3). No significant biomechanical effects
could be found for the contra lateral, unbroken femurs.
Discussion
In contrast to our previous results, we could not demon-
strate an effect on cross-sectional area. This, combined
with a general increase in biomechanical parameters,
seems to point to the possibility of improved material
properties, indicating an increased callus maturity with
more bone. Such an increase would be in line with several
in vitro studies, which have reported an increase in oste-
oblast differentiation and calcification by statins[4-6,21-
25]. We could not demonstrate improved maturity by his-
tology in our previous study with orally administered sim-
vastatin. The difference between that study and the
present one could be due to different local doses (as has
been suggested as a possibility by Maritz et al[12]) or a
failure to detect actual effects.
Table 1: Three-point bending (beam length 6 mm) of healing 
mice femur fractures at 14 days treated with daily subcutaneous 
injections of simvastatin
Treatment n Days Force at 
Failure (F)
Energy 
Uptake 
(Nmm)
Area (mm2) Young's 
modulus 
(MPa)
ms dms d ms dm s d
Simvastatin 10 14 4.4 1.9 1.6 0.9 11.1 2.4 666 1440
Control 8 14 4.1 1.3 1.7 1.0 11.3 2.2 437 705
p 0.68 0.88 0.82 0.69
M signifies mean, SD signifies standard deviation.
Photographs of fractured femurs taken at 14 days post-oper- ative Figure 3
Photographs of fractured femurs taken at 14 days post-oper-
ative. Figure 3b shows positioning of the intramedullary can-
nula.
A 
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Enhanced repair by local simvastatin has been demon-
strated in a critical size defect model in rabbits[9,11], and
there are plentiful in vitro data which support an anabolic
effect on bone by statins [5,23,26-30]. Furthermore, it
seems that, at least for this mice model, a sustained con-
tinuous release is necessary for an effect. From our experi-
ments, it seems clear that the in vivo effects of simvastatin
on bone is a local phenomenon not related to the estab-
lished cholesterol-lowering effect, and that a local delivery
system can be as effective as systemic treatment in pro-
moting fracture healing.
From personal communication with Mundy's group, we
had learned that above a certain dose, the statins did not
have any effect on bone in their experiments. Further,
indirect evidence for a possible biphasic effect on bone
comes from research into possible angiogenesis effects of
statins[31], and there seems to be quite a flat dose-
response curve[32]. Therefore, to get the desired effect,
one should perhaps maintain a certain local concentra-
tion of the drug over a longer period of time. This is what
we most probably achieved in our previous study by mix-
ing the drug in the feed, since mice eat more or less con-
tinuously throughout the day. In contrast, and similar to
subcutaneous injections, gavage should lead to a high but
relatively brief concentration peak of the drug. Such a reg-
imen has been reported to have little effect in mice [13].
Conclusion
In conclusion, we found an effect of simvastatin treatment
directly applied to the fracture area. Our current results are
in parity with what we saw in the first study with orally
administered simvastatin[14]. In that study, the required
doses were excessive. By using local treatment we were
able to reduce the total dose by three orders of magnitude.
The resultant negligible systemic levels bring us one step
closer to the feasibility of using statins to improve fracture
healing in a clinical setting. A natural next step would be
to deliver the simvastatin coated to the implants, as we
have previously successfully done with bisphospho-
nates[33].
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